This Combined Synopsis/Solicitation opportunity from Department Of Health And Human Services was posted on June 23, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.
Four (4) each Genomic Sequencing Systems
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
Active Opportunities Like This One
AI Contract Overview
The FDA is procuring four Illumina MiSeq i100 Plus genomic sequencing systems, along with the DRAGEN Bio-IT secondary analysis platform or acceptable equivalents, to replace aging sequencers within its Human Foods Program. This acquisition is strictly restricted to brand name or equal systems to ensure continuity of established sequencing methods, proprietary flow cells, reagents, software licenses, and manufacturer-supported components critical for mission-critical food safety surveillance, regulatory compliance, and genomic application development. The systems must be delivered unopened with on-site installation at four specified locations—CPK1 in College Park, MD; MOD1 in Laurel, MD; Moffett in Bedford Park, IL; and the FDA Gulf Coast Seafood Lab in Dauphin Island, AL—within six weeks of award. Each system must include an embedded touchscreen monitor, on-instrument computer with integrated control software, pre-installed DRAGEN Bio-IT pipelines, initial reagent kits for verification, and a 12-month comprehensive warranty that commences upon Government acceptance. In addition to delivery and installation, the contractor must provide four in-person system verification and researcher training sessions per site, documented and completed at each location. All hardware, firmware, and software must comply with FDA and HHS information security standards, and contractor personnel entering FDA facilities must undergo background investigations, sign non-disclosure agreements, and be escorted at all times. No Personally Identifiable Information will be processed by the equipment. The contract includes four optional one-year periods for preventative maintenance services, with a maximum total duration of five years including the base warranty. This is a Lowest Price Technically Acceptable procurement, where offers must meet all salient technical requirements to be considered, and award will be made to the lowest-priced technically acceptable offeror. Compliance with Buy American and Trade Agreements clauses is required, and offerors must submit their Unique Entity Identifier, active SAM.gov registration, country of origin for items, and confirm adherence to required FAR representations and certifications. All invoices must be submitted electronically through the Treasury’s Invoice Processing Platform, accompanied by a detailed invoice log addendum, and payment is contingent upon Government acceptance of delivered items and certification that services conform to technical requirements.
General Info
Agency
NAICS
Place of Performance
MD, USASet-Aside
Timeline
Submission Closed
Organization & Contact Information
Full Description
This acquisition is restricted to brand name or equal: Illumina MiSeq i100 Plus and Illumina DRAGENTM Bio-IT Platform because these systems will replace aging sequencers currently owned by the FDA. FDA needs continuity of maintaining the same sequencing methods, proprietary flow cells and reagents or equal, software licenses, and manufacturer-supported components necessary to operate mission driven project continuity.
1. Purpose
The purpose of this procurement is to acquire four (4) Illumina MiSeq i100 Plus desktop genomic sequencing systems to support the FDA’s Human Foods Program (HFP). These systems will replace aging sequencers currently in use and enable high-throughput, cost-effective, and rapid sequencing critical for food safety surveillance, regulatory compliance, and the development of novel genomic applications. The acquisition directly supports FDA's mission to enhance public health through timely detection and characterization of foodborne pathogens in regulated products.
*****************Amendment 0001 to RFQ-FDA-133845-133915 ****************
1. Description:
The purpose of this amendment is to do the following:
- To provide questions and responses submitted in response to RFQ posted on SAM.gov under Solicitation ID: RFQ-FDA-133845-133915
All other terms and conditions remain unchanged.
See attachment "Amendment_01_RFQ-FDA-133845-133915_QA" for Questions and Responses.
More opportunities from Department Of Health And Human Services → FDA Office Of Acq Grant Svcs
Same awarding agency
Find Active Opportunities Like This
Get AI-powered intelligence on the opportunities still open
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 650+ contractors already using CLEATUS
